Doris Duke Foundation Offers Awards Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

NEW YORK-The Doris Duke Charitable Foundation has established the Doris Duke Distinguished Clinical Scientist Award Program, a $12 million initiative to fund the research teams of four eminent scientists studying cancer, AIDS, heart disease, and sickle cell anemia and related blood disorders. Recipients of the first awards are expected to be named in late 1999.

NEW YORK—The Doris Duke Charitable Foundation has established the Doris Duke Distinguished Clinical Scientist Award Program, a $12 million initiative to fund the research teams of four eminent scientists studying cancer, AIDS, heart disease, and sickle cell anemia and related blood disorders. Recipients of the first awards are expected to be named in late 1999.

Each funded researcher will receive a grant of up to $600,000 a year for 5 years. Awardees will focus on “bench to bedside” research. They will be expected to play a major role in their institutions in bridging the gap between bench science and clinical research and promote the development of a new generation of clinical scientists.

The Foundation will solicit application submissions from senior clinical scientists at the 25 medical schools that receive the greatest amount of support from the National Institutes of Health in each of the four disease areas.

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content